Clinical trials: Cancer of the Liver
Solid Tumor
Study of EOC317 in Chinese Patients With Advanced Solid Tumors
This is an open-label, single-arm phase 1, dose escalation study of EOC317 in patients with advanced solid tumors.
- Trial name
- NCT03583125
- Testing
- EOC317
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Taizhou EOC Pharma Co., Ltd.
Hepatocellular Carcinoma
A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
This is a multicenter, open-label, stratified, randomized study to evaluate the safety, tolerability, antitumor activity, pharmacokinetics, pharmacodynamics, and immunogenicity of durvalumab or tremelimumab monotherapy, or…
- Trial name
- NCT02519348
- Testing
- Tremelimumab, Durvalumab, Bevacizumab
- Where
- 44 sites in United States, China and 7 more
- Volunteers
- 433 people
- Sponsor
- MedImmune LLC
Colorectal Neoplasms, Liver Neoplasms
Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases
The study was terminated early due to low enrollment with only 2 subjects enrolled and treated after being open for enrollment for over a year. Therefore, no meaningful efficacy analyses could be performed.
- Trial name
- NCT00106054
- Testing
- Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Pfizer
Hepatocellular Carcinoma (HCC)
Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)
- Trial name
- GPC3 (NCT06726161)
- Testing
- RYZ811, RYZ801
- Where
- 13 sites in United States
- Volunteers
- 590 people
- Sponsor
- RayzeBio, Inc.
Hepatocellular,Carcinoma
Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients
This is a randomized, double-blinded, placebo-controlled, multi-center Clinical Trial. Patients with no tumor lesions one month after resection of hepatocellular carcinoma will be randomized in a 1:1 ratio to 1 of the 2 treatment…
- Trial name
- NCT01489566
- Testing
- Tyroserleutide for injection ,chemotherapy(mitomycin, and Fluorouracil )
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Hepatocellular Carcinoma
First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours…
- Trial name
- RHEA-1 (NCT06795022)
- Testing
- AZD9793 Intravenous (IV) monotherapy, AZD9793 Subcutaneous (SC) monotherapy
- Where
- 21 sites in United States, China and 5 more
- Volunteers
- 304 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma, Cholangiocarcinoma, Intrahepatic
Study of GNS561 in Patients With Liver Cancer
This is a first in human, open-label dose escalation study to investigate the safety, tolerability and pharmacokinetics of GNS561 in patients Primary and Secondary liver cancer
- Trial name
- NCT03316222
- Testing
- GNS561
- Where
- 5 sites in United States, Belgium and 1 more
- Volunteers
- 50 people
- Sponsor
- Genoscience Pharma
Advanced Liver Cancer
A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma
This is a phase Ib/II trial to evaluate the safety, pharmacokinetics and preliminary efficacy of QL1706 or QL1604 combined with bevacizumab in patients with advanced hepatocellular carcinoma.
- Trial name
- NCT05603039
- Testing
- QL1706, QL1604, Bevacizumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Hepatocellular Cancer, Liver Cancer
Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the efficacy and safety of BGB-B2033 monotherapy in adults with hepatocellular carcinoma who have previously been treated with anti-programmed cell death protein 1 (PD-1)/programmed…
- Conditions
- Hepatocellular Cancer, Liver Cancer, Hepatocellular Carcinoma
- Trial name
- NCT07911683
- Testing
- BGB-B2033
- Volunteers
- 100 people
- Sponsor
- BeOne Medicines
Hepatocellular Carcinoma
PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
This is a multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in the first-line treatment of subjects with inoperable HCC.
- Trial name
- NCT05864105
- Testing
- PM8002, FOLFOX regimen
- Where
- 9 sites in China
- Volunteers
- 35 people
- Sponsor
- Biotheus Inc.
Hepatocellular Carcinoma (HCC)
The Phase II Study of Icaritin in Patients With Advanced Hepatocellular Carcinoma
The primary objective of the study is to assess the time to progression (TTP) in patients with advanced HCC treated with Icaritin .
- Trial name
- NCT01972672
- Testing
- Icaritin
- Where
- 3 sites in China
- Volunteers
- 70 people
- Sponsor
- Beijing Shenogen Biomedical Co., Ltd
Advanced Hepatocellular Carcinoma, Hepatocellular Carcinoma
Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527, and to assess the safety, tolerability and pharmacokinetics of H3B-6527.
- Conditions
- Advanced Hepatocellular Carcinoma, Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasms
- Trial name
- NCT02834780
- Testing
- H3B-6527
- Where
- 44 sites in United States, Belgium and 9 more
- Volunteers
- 128 people
- Sponsor
- H3 Biomedicine Inc.
Carcinoma, Hepatocellular
c-Met Second-Line Hepatocellular Carcinoma
This is a Phase 1b/2, multicenter, single arm trial to assess the efficacy, safety, and pharmacokinetics (PK) of MSC2156119J as monotherapy in subjects with MET+ advanced hepatocellular carcinoma (HCC) with child Pugh Class A…
- Trial name
- NCT02115373
- Testing
- Tepotinib
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Hepatocellular Carcinoma
Immunotherapy for Advanced Liver Cancer
This is a randomized, controlled multi-site, multi-national clinical trial conducted in Thailand and Malaysia for Asian adults (males or females), 18 years of age and older presenting with advanced HCC (BCLC stage C) including…
- Trial name
- ALIVE (NCT05033522)
- Testing
- AlloStim® immunotherapy, FOLFOX regimen, Sorafenib
- Where
- 8 sites in Malaysia, Thailand
- Volunteers
- 150 people
- Sponsor
- Mirror Biologics, Inc.
Liver Fibrosis, HEPATITIS B CHRONIC
A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients
The purpose of this study is to determine whether an investigational drug DCB-BO1202 is effective and safe in the treatment of liver fibrosis in HBV patients having experienced intermediate stage hepatocellular carcinoma (HCC)
- Conditions
- Liver Fibrosis, HEPATITIS B CHRONIC, Hepatocellular Carcinoma
- Trial name
- NCT02289300
- Testing
- DCB-BO1202
- Where
- Taiwan
- Sponsor
- A2 Healthcare Taiwan Corporation
Colorectal Neoplasms, Neoplasm Metastasis
Health Economic Evaluation of Primovist-enhanced Liver MRI
Patients with a history of colorectal cancer and known or suspected liver metastases who are scheduled for contrast-enhanced tomographic imaging will be included in this study.
- Trial name
- NCT00764621
- Testing
- Primovist MRI, Extracellular contrast media (ECCM) MRI, Contrast-enhanced CT
- Where
- 44 sites in Austria, Germany and 7 more
- Volunteers
- 360 people
- Sponsor
- Bayer
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
The primary objective of this study was to assess the preliminary antitumor activity as indicated by overall response rate (ORR) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or…
- Conditions
- Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT04401800
- Testing
- Lenvatinib, Tislelizumab
- Where
- 9 sites in China
- Volunteers
- 64 people
- Sponsor
- BeiGene
Hepatoblastoma, Hepatocellular Carcinoma (HCC)
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are…
- Conditions
- Hepatoblastoma, Hepatocellular Carcinoma (HCC), Liver Neoplasms, Metastatic Liver Cancer
- Trial name
- ARYA-2 (NCT04634357)
- Testing
- ET140203 T Cells
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Eureka Therapeutics Inc.
Cancer, Lung, Cancer Liver
PixelShine vs. Iterative Reconstruction (IR) Processing of CT Images
This study will compare the quality of CT images acquired with very low-dose radiation and processed with commercially available software vs. PixelShine processed images.
- Conditions
- Cancer, Lung, Cancer Liver, X-rays; Effects
- Trial name
- NCT03033615
- Testing
- PixelShine, Conventional processing
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- AlgoMedica, Inc.
HCC, Hepatocellular Carcinoma
A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC
This is a Phase II, randomized, open-label, global, multi-center study to compare the efficacy and safety of AK104 in combination with lenvatinib versus lenvatinib in patients with advanced hepatocellular carcinoma who have…
- Trial name
- NCT06984718
- Testing
- AK104+lenvatinib, lenvatinib
- Volunteers
- 120 people
- Sponsor
- Akeso